Cart
sales@molnova.com
NSC23005 sodium
CAS No. 1796596-46-7
NSC23005 sodium ( NSC 23005 sodium;NSC-23005 sodium;p18-IN-40 )
Catalog No. M12713 CAS No. 1796596-46-7
A novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | In Stock |
|
| 5MG | 77 | In Stock |
|
| 10MG | 105 | In Stock |
|
| 25MG | 231 | In Stock |
|
| 50MG | 413 | In Stock |
|
| 100MG | 592 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNSC23005 sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM.
-
DescriptionA novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM; inhibits p18, and then activates CDK4/6, promotes HSCs expansion in both murine and human models; shows no activity in promoting the proliferation of leukemia cells, and no significant cytotoxicity toward 32D cells or HSCs.
-
SynonymsNSC 23005 sodium;NSC-23005 sodium;p18-IN-40
-
PathwayAngiogenesis
-
TargetCDK
-
Recptorp18INK4C
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1796596-46-7
-
Formula Weight305.33
-
Molecular FormulaC13H16NNaO4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6.4 mg/mL (Need ultrasonic)
-
SMILESC1CCC(CC1)NS(=O)(=O)C2=CC=C(C=C2)C(=O)[O-].[Na+]
-
Chemical NameBenzoic acid, 4-[(cyclohexylamino)sulfonyl]-, sodium salt (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xie XQ, et al. Sci Rep. 2015 Dec 18;5:18115.
molnova catalog
related products
-
Palbociclib (PD03329...
Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM.
-
Ibulocydine
Ibulocydine is the prodrug of CDK inhibitor BMK-Y101, inhibits CDK7 and CDK9 with IC50 of 530 nM and 85 nM in kinase assays, respectively.
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
